Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867381 · ClinicalTrials.gov registry record · NA
Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History
A NA study of Atherosclerosis and Air Pollution, sponsored by University of Southern California.
- Recruiting
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT05867381: Recruiting NA study of Atherosclerosis and Air Pollution, sponsored by University of Southern California.
NCT05867381 is a NA study of Atherosclerosis and Air Pollution that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 112 participants, below the 1,064-participant average among 69 other Atherosclerosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05867381, a NA study of Atherosclerosis and Air Pollution, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.
Primary Outcome
Differences between baseline and systolic and diastolic blood pressure measured during and after intervention
Conditions Studied
Interventions
- DEVICE HEPA filtration
- DEVICE Sham filtration
Study Locations (1)
California
- Keck School of Medicine, University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05867381 shows while recruiting
NCT05867381 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 1,064-participant average among 69 other Atherosclerosis trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which HEPA filtration is the first listed.
NCT05867381 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05867381 about?
NCT05867381 is a clinical study titled "Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History". This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.
What is the current status of trial NCT05867381?
This trial is currently recruiting. It is a NA study. The enrollment target is 112 participants. The study started on 2023-07-11. Estimated completion is 2027-06-30.
What conditions does trial NCT05867381 study?
This clinical trial studies the following conditions: Atherosclerosis, Air Pollution.
What interventions are being tested in trial NCT05867381?
The interventions under investigation include: HEPA filtration (DEVICE), Sham filtration (DEVICE).
Who is sponsoring clinical trial NCT05867381?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05867381 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05867381's enrollment target sits among peer trials
112 49th of 69 higher than 21 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
New Heart Imaging Techniques to Evaluate Possible Heart Disease
RECRUITING · NA
-
Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study
RECRUITING · NA
-
High Protein Diet and Atherosclerosis
RECRUITING · NA
-
The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI